Article Date: 17 Nov 2012 – 0:00 PST

 

Inflexxion’s NAVIPPRO data indicate the tamper resistant reformulation results in less abuse by injection and snorting

• Aims of this study were to assess 1) whether the rates of abuse of extended-release (ER) oxycodone(OxyContin®) decline following introduction of reformulated ER oxycodone (ORF), and 2) whether ORF is less likely to be abused through non-oral routes of administration that require tampering
• Researchers obtained data from 140,496 individuals assessed for substance abuse treatment at 357 treatment centers
• Findings were consistent with the goals for a tamper resistant formulation, however further research is needed to determine the persistence and generalizability of these initial findings

This is the first epidemiological study to examine the public health impact of a tamper resistant extended-release oxycodone (ORF). ER oxycodone was reformulated with physicochemical barriers to crushing and dissolving intended to reduce abuse through non-oral routes of administration. Manufacturer shipments of original ER oxycodone stopped on August 5, 2010, and ORF shipments started August 9, 2010. During the first 20 months following ORF introduction, it was abused significantly less than the original ER oxycodone when measured by 8 outcome measures, particularly through non-oral routes of administration that require tampering (such as injection, snorting, smoking). Read More…